Literature DB >> 9883553

Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screenings.

S G Baker1.   

Abstract

To evaluate various ages to begin periodic breast cancer screening, we propose a method of analysis that can be applied to either a nonrandomized or a randomized study involving only a few screenings at regular intervals. For the analysis of data from a nonrandomized study, we assume (i) once breast cancer can be detected on screening and confirmed by biopsy, it will stay that way; (ii) given age, the probability of breast cancer detection does not depend on year of birth; and (iii) subjects who refuse screening have the same rates of breast cancer mortality following diagnosis as screened subjects had they not received screening. The key idea is that older screened subjects are controls for younger screened subjects. For the analysis of data from a randomized study, we relax assumption (iii). Based on the HIP randomized trial and assumptions (i) and (ii), we estimate that starting periodic breast cancer screening with mammography and physical examination at age 40 instead of age 50 reduces breast cancer mortality by 14 per 10,000 with a 95% confidence interval of (-4/10,000, 32/10,000). This must be weighted against an estimated increase in the number of biopsies that do not detect cancer of 580 per 10,000 with a 95% confidence interval of (520/10,000, 650/10,000).

Entities:  

Mesh:

Year:  1998        PMID: 9883553

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

2.  When to initiate cancer screening exam?

Authors:  Dongfeng Wu
Journal:  Stat Interface       Date:  2022-03-04       Impact factor: 0.716

3.  Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening.

Authors:  Stuart G Baker; Diane Erwin; Barnett S Kramer; Philip C Prorok
Journal:  BMC Med Res Methodol       Date:  2003-03-06       Impact factor: 4.615

4.  Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.

Authors:  Justin Shows; Dongfeng Wu
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

5.  Statistical issues in randomized trials of cancer screening.

Authors:  Stuart G Baker; Barnett S Kramer; Philip C Prorok
Journal:  BMC Med Res Methodol       Date:  2002-09-19       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.